Kevin Robert Lind

CIK: 0001677036

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (4.5%)

Derivative conversions

Awards (A)11 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)10 (45.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

AVTX

Avalo Therapeutics, Inc.

Director

APMD

Apnimed, Inc.

DirectorOfficer

LBPH

Longboard Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (22 total)

AVTX
Avalo Therapeutics, Inc.
Sep 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.4K shares at avg. $12.29-
APMD
Apnimed, Inc.
Aug 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.2M shares-
APMD
Apnimed, Inc.
Aug 3, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
74.1K shares-
APMD
Apnimed, Inc.
Aug 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
74.1K shares-
APMD
Apnimed, Inc.
Aug 3, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
1.2M shares-
APMD
Apnimed, Inc.
Aug 3, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
108.9K shares-
APMD
Apnimed, Inc.
Aug 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
108.9K shares-
APMD
Apnimed, Inc.
Jul 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
108.9K shares-
AVTX
Avalo Therapeutics, Inc.
Jun 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.1K shares at avg. $15.04-
AVTX
Avalo Therapeutics, Inc.
Jun 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20.1K shares-
AVTX
Avalo Therapeutics, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.4K shares at avg. $12.13-
AVTX
Avalo Therapeutics, Inc.
Dec 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
848 shares at avg. $14.74-
AVTX
Avalo Therapeutics, Inc.
Oct 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
40.2K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Disposition(D)
Employee Stock Option (right to buy)
Direct
255.4K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Tender Offer(U)
Direct
363.7K shares at avg. $60.00$21.8M
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Disposition(D)
Employee Stock Option (right to buy)
Direct
192.8K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Disposition(D)
Employee Stock Option (right to buy)
Direct
325.9K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Disposition(D)
Restricted Stock Unit
Direct
22K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Dec 2, 2024
Disposition(D)
Employee Stock Option (right to buy)
Direct
332.1K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Nov 13, 2024
Gift(G)
Direct
80K shares-
LBPH
Longboard Pharmaceuticals, Inc.
Nov 13, 2024
Exercise(M)
Direct
12.8K shares at avg. $3.12$40K
LBPH
Longboard Pharmaceuticals, Inc.
Oct 25, 2024
Award(A)
Retention Restricted Stock Units
Direct
22K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,352	$12.29	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Award(A) Stock Option (Right to Buy)	1,186,278	-	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Disposition(D) Stock Option (Right to Buy)	74,128	-	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Award(A) Stock Option (Right to Buy)	74,128	-	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Disposition(D) Stock Option (Right to Buy)	1,186,278	-	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Disposition(D) Stock Option (Right to Buy)	108,916	-	-	Direct
Aug 3, 2026	APMD Apnimed, Inc.	Award(A) Stock Option (Right to Buy)	108,916	-	-	Direct
Jul 30, 2026	APMD Apnimed, Inc.	Award(A) Stock Option (Right to Buy)	108,916	-	-	Direct
Jun 30, 2026	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,105	$15.04	-	Direct
Jun 2, 2026	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,100	-	-	Direct
Mar 31, 2026	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,370	$12.13	-	Direct
Dec 31, 2025	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	848	$14.74	-	Direct
Oct 1, 2025	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	40,200	-	-	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Disposition(D) Employee Stock Option (right to buy)	255,377	-	-	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Tender Offer(U)	363,740	$60.00	$21,824,400	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Disposition(D) Employee Stock Option (right to buy)	192,783	-	-	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Disposition(D) Employee Stock Option (right to buy)	325,850	-	-	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Disposition(D) Restricted Stock Unit	22,000	-	-	Direct
Dec 2, 2024	LBPH Longboard Pharmaceuticals, Inc.	Disposition(D) Employee Stock Option (right to buy)	332,134	-	-	Direct
Nov 13, 2024	LBPH Longboard Pharmaceuticals, Inc.	Gift(G)	80,000	-	$0	Direct
Nov 13, 2024	LBPH Longboard Pharmaceuticals, Inc.	Exercise(M)	12,808	$3.12	$40,002	Direct
Oct 25, 2024	LBPH Longboard Pharmaceuticals, Inc.	Award(A) Retention Restricted Stock Units	22,000	-	-	Direct

1-22 of 22 transactions

About Lind Kevin Robert

Lind Kevin Robert (SEC CIK 0001677036) files insider reports with the SEC as Director of Avalo Therapeutics, Inc. (AVTX), Chief Executive Officer of Apnimed, Inc. (APMD) and President and CEO of Longboard Pharmaceuticals, Inc. (LBPH).

Signal8 holds 12 ownership filings by Lind Kevin Robert (2 Form 3, 10 Form 4), filed between Oct 29, 2024 and Oct 2, 2026. Those filings report 22 transactions, from Oct 25, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lind Kevin Robert's filings is in WAYNE, PA.

Recent filings by Lind Kevin Robert

Sep 30, 2026: Grant or award of AVTX derivative securities (Form 4, code A).
Aug 3, 2026: Grant or award of APMD derivative securities (Form 4, code A).
Aug 3, 2026: Disposition to issuer transaction of APMD derivative securities (Form 4, code D).
Aug 3, 2026: Grant or award of APMD derivative securities (Form 4, code A).
Aug 3, 2026: Disposition to issuer transactions of APMD derivative securities (2 lines, Form 4, code D).

Other insiders filing for Avalo Therapeutics, Inc. (AVTX)

Jain Rita, Director
Philip Ron M, Director
Sullivan Christopher Ryan, Chief Financial Officer
Doyle Mittie, Chief Medical Officer
Riley Jennifer, Chief Strategy Officer
VARKI PAUL, Chief Legal Officer

How to read Form 4 transaction codes